Get the Stockscreener App
13.98
2.31%
-0.33
Replimune Group Inc stock is traded at $13.98, with a volume of 656.76K.
It is down -2.31% in the last 24 hours and up +17.97% over the past month.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
See More
Previous Close:
$14.31
Open:
$14.72
24h Volume:
656.76K
Relative Volume:
0.75
Market Cap:
$1.08B
Revenue:
-
Net Income/Loss:
$-209.96M
P/E Ratio:
-4.4241
EPS:
-3.16
Net Cash Flow:
$-176.27M
1W Performance:
-0.85%
1M Performance:
+17.97%
6M Performance:
+36.12%
1Y Performance:
+82.98%
1-Day Range:
$13.57
$14.80
1-Week Range:
$13.40
$14.80
52-Week Range:
$4.92
$17.00
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group Inc
Sector
Industry
Phone
(781) 222-9600
Address
500 UNICORN PARK, WOBURN, MA
Compare REPL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
13.98 | 1.08B | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Apr-17-23 | Resumed | Piper Sandler | Overweight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-17-20 | Initiated | BTIG Research | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-15-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-20 | Initiated | Barclays | Overweight |
| Sep-04-19 | Initiated | ROTH Capital | Buy |
| Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| Apr-25-19 | Initiated | Wedbush | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-14-18 | Initiated | JP Morgan | Overweight |
| Aug-14-18 | Initiated | Leerink Partners | Outperform |
View All
Replimune Group Inc Stock (REPL) Latest News
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Replimune Group, Inc. (NASDAQ:REPL) Short Interest Update - MarketBeat
Replimune's SWOT analysis: oncolytic immunotherapy stock poised for FDA approval - Investing.com India
Possible Bearish Signals With Replimune Group Insiders Disposing Stock - Simply Wall St
HC Wainwright Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock Price - MarketBeat
Leerink Partnrs Predicts Weaker Earnings for Replimune Group - Defense World
FY2025 EPS Estimates for Replimune Group Lowered by Wedbush - MarketBeat
Replimune Group (NASDAQ:REPL) Announces Quarterly Earnings Results - MarketBeat
Replimune stock target raised to $22 at H.C. Wainwright - MSN
Navigating Uncertainty: Replimune Group’s Strategic Challenges Amid Clinical Trials and Global Risks - MSN
Replimune stock target raised to $22 at H.C. Wainwright By Investing.com - Investing.com Australia
Replimune: A Misunderstood Contender In Oncolytics (NASDAQ:REPL) - Seeking Alpha
Wedbush Raises Replimune Group's Price Target to $19 From $16, Keeps Outperform Rating - Marketscreener.com
Replimune Group Inc. (REPL) reports earnings - Quartz
Replimune Group, Inc. SEC 10-Q Report - TradingView
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
FDA Fast-Tracks Replimune's Melanoma Treatment as Cash Reserves Hit $536M in Q3 Report - StockTitan
Top Wealth Group Holding Ltd (TWG)’s financial ratios: A comprehensive overview - The Dwinnex
Metric Analysis: Nvni Group Ltd (NVNI)’s Key Ratios in the Limelight - The Dwinnex
Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Replimune Group (REPL) Projected to Post Quarterly Earnings on Thursday - MarketBeat
How to Take Advantage of moves in (REPL) - Stock Traders Daily
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Replimune's Strategic Move: $14.25 Stock Options Package Secures Top Talent - StockTitan
Replimune Group (REPL) Expected to Announce Earnings on Thursday - Defense World
Holdings of Replimune Group Inc (REPL) are aligned with the stars - SETE News
SG Americas Securities LLC Acquires 3,374 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Was there any good news for Replimune Group Inc (REPL) stock in the last session? - US Post News
Upward Trajectory: Replimune Group Inc (REPL) Posts a Slidee, Closing at 13.71 - The Dwinnex
Vanguard Group Inc's Strategic Acquisition of Replimune Group In - GuruFocus.com
Replimune Raises $55 Million To Advance Its Oncolytic Immunotherapy Programs - Bain Capital
Replimune Group, Inc. (NASDAQ:REPL) Receives $19.14 Average Target Price from Analysts - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Receives $19.14 Consensus PT from Analysts - MarketBeat
Replimune Group (NASDAQ:REPL) Stock Price Down 3.5%What's Next? - MarketBeat
What is Wedbush’s Estimate for Replimune Group Q3 Earnings? - Defense World
What is Wedbush's Estimate for Replimune Group Q3 Earnings? - MarketBeat
Replimune price target raised to $21 from $17 at H.C. Wainwright - Yahoo Finance
Replimune Group (NASDAQ:REPL) Shares Up 6% After Analyst Upgrade - Defense World
Replimune's SWOT analysis: oncolytic immunotherapy stock faces pivotal year - MSN
Replimune announces priority review for its melanoma treatment - MSN
BMO Capital Markets Forecasts Strong Price Appreciation for Replimune Group (NASDAQ:REPL) Stock - MarketBeat
REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA - Yahoo Finance
FDA accepts Replimune’s melanoma candidate for priority review - The Pharma Letter
Replimune Group (NASDAQ:REPL) Price Target Raised to $21.00 at HC Wainwright - MarketBeat
Replimune stock price target raised to $27 by BMO Capital - Investing.com Canada
Replimune stock soars on FDA priority review for melanoma treatment - MSN
Barclays maintains Replimune stock with $17 target By Investing.com - Investing.com Canada
Replimune Group Inc Stock (REPL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):